Medtronic and Orchestra BioMed Collaborate on Global Study for Hypertension Therapy

Medtronic has collaborated with Orchestra BioMed on a global study for hypertension therapy, showcasing positive outcomes from their AVIM therapy for patients requiring pacemakers due to uncontrolled hypertension. The study found that AVIM therapy effectively reduced systolic blood pressure and enhanced left ventricular volumes, suggesting beneficial reverse remodeling of the left ventricle. Medtronic is a leading medical technology company with a diverse portfolio of therapeutic devices, reporting a revenue of $34.2 billion and a robust operating margin of 19.43%. The company maintains a solid liquidity position and a manageable level of debt relative to equity.

Medtronic, a leading medical technology company, has collaborated with Orchestra BioMed on a global study to evaluate the efficacy of AVIM therapy for patients requiring pacemakers due to uncontrolled hypertension. The study, conducted in collaboration with Medtronic, demonstrated that AVIM therapy effectively reduced systolic blood pressure and enhanced left ventricular volumes, suggesting beneficial reverse remodeling of the left ventricle.

The study, titled "Pressure-Volume Analysis Demonstrates Short- and Long-Term Hemodynamic Effects of Atrioventricular Interval Modulation Therapy in Hypertension," was published in the Journal of the American College of Cardiology: Clinical Electrophysiology. The research involved an invasive pressure-volume loop analysis in 16 hypertensive pacemaker-indicated subjects, as well as a noninvasive analysis from a subgroup of 32 subjects from the MODERATO II study. The findings showed that AVIM therapy reduced systolic blood pressure acutely by decreasing cardiac preload and effective arterial elastance, with significant reductions of 17.1 mmHg and 19.2 mmHg, respectively, compared to standard dual-chamber pacing [1].

The study also highlighted improvements in left ventricular hemodynamics, with both RV pacing and CSP lead placements showing favorable effects. The therapy demonstrated reduced cardiac workload and total peripheral resistance, with no adverse impact on stroke volume or contractility. These findings suggest that AVIM therapy has the potential to induce positive reverse remodeling of ventricular hypertrophy, potentially preventing or treating heart failure [1].

Medtronic, with a diverse portfolio of therapeutic devices, reported a revenue of $34.2 billion and a robust operating margin of 19.43% in the latest financial period. The company maintains a solid liquidity position and a manageable level of debt relative to equity. This collaboration with Orchestra BioMed is a significant step in the development of innovative therapies for hypertension, a leading risk factor for death worldwide.

References:
[1] https://finance.yahoo.com/news/orchestra-biomed-announces-publication-clinical-113000234.html